TY - JOUR
T1 - Substrate Ablation of Ventricular Tachycardia
T2 - Late Potentials, Scar Dechanneling, Local Abnormal Ventricular Activities, Core Isolation, and Homogenization
AU - Briceño, David F.
AU - Romero, Jorge
AU - Gianni, Carola
AU - Mohanty, Sanghamitra
AU - Villablanca, Pedro A.
AU - Natale, Andrea
AU - Di Biase, Luigi
N1 - Funding Information:
Disclosures: Dr L. Di Biase is a consultant for Stereotaxis, Biosense Webster, Boston Scientific, and St. Jude Medical. Dr L. Di Biase received speaker honoraria/travel from Medtronic, Janssen, Pfizer, EPiEP, and Biotronik. Dr A. Natale has received speaker honoraria from Boston Scientific, Biosense Webster, St. Jude Medical, Biotronik, and Medtronic and is a consultant for Biosense Webster, St. Jude Medical, and Janssen. The remaining authors have no disclosures.
Publisher Copyright:
© 2016 Elsevier Inc.
PY - 2017/3/1
Y1 - 2017/3/1
N2 - Ventricular arrhythmias are a frequent cause of mortality in patients with ischemic cardiomyopathy and nonischemic cardiomyopathy. Scar-related reentry represents the most common arrhythmia substrate in patients with recurrent episodes of sustained ventricular tachycardia (VT). Initial mapping of scar-related VT circuits is focused on identifying arrhythmogenic tissue. The substrate-based strategies include targeting late potentials, scar dechanneling, local abnormal ventricular activities, core isolation, and homogenization of the scar. Even though substrate-based strategies for VT ablation have shown promising outcomes for patients with structural heart disease related to ischemic cardiomyopathy, the data are scarce for patients with nonischemic substrates.
AB - Ventricular arrhythmias are a frequent cause of mortality in patients with ischemic cardiomyopathy and nonischemic cardiomyopathy. Scar-related reentry represents the most common arrhythmia substrate in patients with recurrent episodes of sustained ventricular tachycardia (VT). Initial mapping of scar-related VT circuits is focused on identifying arrhythmogenic tissue. The substrate-based strategies include targeting late potentials, scar dechanneling, local abnormal ventricular activities, core isolation, and homogenization of the scar. Even though substrate-based strategies for VT ablation have shown promising outcomes for patients with structural heart disease related to ischemic cardiomyopathy, the data are scarce for patients with nonischemic substrates.
KW - Structural heart disease
KW - Substrate ablation
KW - Ventricular arrhythmia
KW - Ventricular tachycardia
UR - http://www.scopus.com/inward/record.url?scp=85008485949&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85008485949&partnerID=8YFLogxK
U2 - 10.1016/j.ccep.2016.10.014
DO - 10.1016/j.ccep.2016.10.014
M3 - Review article
C2 - 28167088
AN - SCOPUS:85008485949
SN - 1877-9182
VL - 9
SP - 81
EP - 91
JO - Cardiac Electrophysiology Clinics
JF - Cardiac Electrophysiology Clinics
IS - 1
ER -